Is a global biopharmaceutical company known for its albumin products.They have a strong presence in the albumin market, offering both human and bovine-derived albumin products.The company has been focused on research and development efforts to improve albumin-based therapies. Is a Swiss-based company that produces a range of plasma-derived products, including albumin.They have been active in research and development to enhance the safety and efficacy of albumin products. Takeda Pharmaceutical Company Limited (Shire) Leading players operating in the global albumin business are The global albumin industry is quite competitive, with the top ten players accounting for a major share of the market and companies focusing on research and development to produce better pharmaceutical and vaccine products for existing diseases. The contract manufacturing and export of albumin from some Asian countries played a role in the global albumin supply chain. ![]() Countries like China, Japan, and India, showed substantial growth potential in the albumin market. Growing healthcare expenditure, an aging population, and increased adoption of albumin in clinical applications contributed to the market's expansion. A rise in investments in life sciences by a large number of biopharmaceutical companies and research institutes is expected to boost the global market for albumin in these regions throughout the assessment period.Īsia Pacific is expected to account for a significant share of the albumin market during the forecast period. ![]() North America is projected to be a highly attractive market for albumin during the forecast period. Improved albumin purification and production technologies have made it more cost-effective and efficient to manufacture albumin, driving its availability and affordability.įor In-depth Competitive Analysis, Buy Now: Ongoing research and development efforts have expanded the applications of albumin in the pharmaceutical and biotechnology sectors. Market: Key Trends and Opportunistic FrontiersĪlbumin-based therapies and products receive regulatory approvals in different regions, it opens up new markets and opportunities for growth. In terms of product, the human serum albumin segment is anticipated to account for a major market share during the forecast period.īased on end-users, pharmaceutical and biotechnology companies, is expected to generate high revenue during the forecast period. (Merck KGaA), Takeda Pharmaceutical Company Limited (Shire), Other Prominent PlayersĪs of 2022, the albumin market was valued at US$ 5.1 billionīased on application, drug delivery is expected to be the most attractive segment during the forecast period. Ltd., InVitria, Medxbio Pte Ltd., Octapharma AG, RayBiotech, Inc., SeraCare Life Sciences (LGC), Sigma-Aldrich Co. North America, Europe, Asia Pacific, Middle East & Africa, South AmericaĪlbumedix A/S (Novozyme A/S), CSL Behring LLC, Biotest AG, Albumin Therapeutics, LLC, Grifols International, S.A., HiMedia Laboratories Pvt. Request a sample for a glimpse into the market's futureĬonnect with our team of research specialists and unlock the optimal solution for driving your business growth Pharmaceutical companies and biotechnology firms are investing in research and development related to albumin-based therapies, leading to the development of new products and applications. Improvements in albumin purification and production technologies have made it more cost-effective and efficient to manufacture, further driving market growth. Albumin is used in therapies for managing and treating these conditions, leading to a consistent demand. The increasing prevalence of chronic diseases like liver disease, kidney disease, and diabetes are on the rise worldwide. The increasing demand for albumin in the healthcare industry fuels the market demand. ![]() As of 2023, the market for albumin is expected to close at US$ 5.49 billion.Īlbumin is commonly used in hospitals and clinics for treating various medical conditions, including burns, liver disease, and shock. , a valuation of US$ 8.1 billion is anticipated for the market in 2031. Report published by Transparency Market Research ![]() 13, 2023 (GLOBE NEWSWIRE) - The global albumin market is projected to flourish at a CAGR of 6.1% from 2022 to 2031. Wilmington, Delaware, United States, Sept.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |